171 results on '"Branford, Susan"'
Search Results
2. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition
3. CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib
4. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
5. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
6. RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia
7. Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants
8. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
9. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
10. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
11. ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure
12. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
13. Monitoring and defining early response: Where to draw the line?
14. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
15. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
16. A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system
17. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
18. A DNA Real-Time Quantitative PCR Method Suitable for Routine Monitoring of Low Levels of Minimal Residual Disease in Chronic Myeloid Leukemia
19. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
20. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
21. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
22. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
23. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
24. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
25. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
26. Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
27. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
28. Molecular methods in diagnosis and monitoring of haematological malignancies
29. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia
30. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
31. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA
32. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
33. Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia
34. Clonal Architecture of Donor-Derived Myeloid Neoplasms after Allogeneic Hematopoietic Stem Cell Transplant
35. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
36. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
37. Measuring Minimal Residual Disease in Chronic Myeloid Leukemia: Fluorescence In Situ Hybridization and Polymerase Chain Reaction
38. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
39. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
40. Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML
41. High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders
42. Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study
43. Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial
44. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
45. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
46. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
47. Molecular monitoring of BCR– ABL as a guide to clinical management in chronic myeloid leukaemia
48. Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript
49. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission
50. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.